Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-488 in Cutaneous Lupus Erythematosus
NCT07440537Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of icp-488 in cutaneous lupus erythematosus (CLE), sponsored by InnoCare Pharma. Started Apr 2026; status: recruiting.
02
Drugs
icp-488
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07440537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07440537.